The effects of antipsychotic drugs on Fos protein expression in the prefrontal cortex: Cellular localization and pharmacological characterization

Neuroscience

Volumn 70, Issue 2, 1996, Pages 377-389

  Deutch, A Y ^a,b   Duman, R S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

Author keywords

Calbindin; Clozapine; Dopamine; Infralimbic cortex; Interneuron; Serotonin

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CLOZAPINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; HALOPERIDOL; NEUROLEPTIC AGENT; OXAPINE; PRAZOSIN; RACLOPRIDE; REMOXIPRIDE; RITANSERIN; SCOPOLAMINE; SEROTONIN RECEPTOR; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN REGION; CONTROLLED STUDY; GENE EXPRESSION; IMMEDIATE EARLY GENE; IMMUNOBLOTTING; MALE; NONHUMAN; ONCOGENE C FOS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMAL; ANTIPSYCHOTIC AGENTS; BLOTTING, WESTERN; CELL COUNT; CLOZAPINE; FRONTAL LOBE; HALOPERIDOL; IMMUNOHISTOCHEMISTRY; MALE; PROTO-ONCOGENE PROTEINS C-FOS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0029655657     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(95)00357-6     Document Type: Article

References (86)

1. Akbarian S., Bunney W. E. Jr, Potkin S. G., Wigal S. B., Hagman J. O., Sandman C. A. and Jones E. G. (1993) Altered distribution of nicotinamide-adenine dinucleotide phosphate-diaphorase cells in frontal lobe of schizophrenics implies disturbances in cortical development. Arch. gen. Psychiat. 50, 169-177.
2. Alexander G. E., Crutcher M. D. and DeLong M. R. (1990) Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog. Brain Res. 85, 119-146.
3. 3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain. Eur. J. Pharmac. 146, 113-120.
4. Baldessarini R. J. and Frankenburg F. R. (1991) Clozapine: a novel antipsychotic drug. New Engl. J. Med. 324, 746-754.
5. Bannon M. J., Reinhard J. F. Jr, Bunney E. B. and Roth R. H. (1982) Unique response to antipsychotic drugs is due to absence of terminal autoreceptors in mesocortical dopamine neurons. Nature 296, 444-446.
6. Berendse H. W., Galis-de Graaf Y. and Groenewegen H. J. (1992) Topographical organization and relationship with ventral striatal compartments of prefrontal corticostriatal projections in the rat. J. comp. Neurol. 316, 314-347.
7. Berger B., Gaspar P. and Verney C. (1991) Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci. 14, 21-27.
8. Berman K. F. and Weinberger D. R. (1990) The prefrontal cortex in schizophrenia and other neuropsychiatrie diseases: in vivo physiological correlates of cognitive deficits. Prog. Brain Res. 85, 521-538.
9. Berretta S., Robertson H. A. and Graybiel A. M. (1992) Dopamine and glutamate agonists stimulate neuron-specific expression of Fos-like protein in the striatum. J. Neurophysiol. 68, 767-777.
10. Bourdelais A. J. and Deutch A. Y. (1994) The effects of haloperidol and clozapine on extracellular GABA levels in the prefrontal cortex of the rat: an in vivo microdialysis study. Cerebral Cortex 4, 69-77.
11. Brog J. S., Salyapongse A., Deutch A. Y. and Zahm D. S. (1993) The afferent innervation of the core and shell of the accumbens part of the rat ventral striatum: immunohistochemical detection of retrogradely transported Fluorogold. J. comp. Neurol. 338, 255-278.
12. Brown K. W. and White T. (1991) The association among negative symptoms, movement disorders, and frontal lobe psychological deficits in schizophrenic patients. Biol. Psychiat. 30, 1182-1190.
13. lc sites. Eur. J. Pharmac. 191, 93-96.
14. Celio M. R. (1990) Calbindin D-28k and parvalbumin in the rat nervous system. Neuroscience 35, 375-475.
15. Claus A., Bollen J., De Cuyper H., Eneman M., Malfroid M., Peuskens J. and Heylen S. (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicenter double-blind comparative study. Acta psychiat. scand. 85, 295-305.
16. Cohen B. M. and Lipinski L. F. (1986) In vivo potencies of antipsychotic drugs in blocking alpha 1 noradrenergic and dopamine D2 receptors: implications for mechanisms of action. Life Sci. 39, 2571-2580.
17. Csernansky J. G., Wrona C. T., Bardgett M. E., Early T. S. and Newcomer J. W. (1993) Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics. Psychopharmacologia 110, 145-151.
18. Davis K., Kahn R. S., Ko G. and Davidson M. (1992) Dopamine in schizophrenia: a review and reconceptualization. Am. J. Psychiat. 148, 1474-1486.
19. DeFilipe J., Hendry S. H. C. and Jones E. G. (1989) Visualization of chandelier cell axons by parvalbumin immunoreactivity in monkey cerebral cortex. Proc. natn. Acad. Sci. U.S.A. 86, 2093-2097.
20. DeFilipe J., Hendry S. H. C. and Jones E. G. (1989) Synapses of double bouquet cells in monkey cerebral cortex visualized by calbindin immunoreactivity. Brain Res. 503, 49-54.
21. Deutch A. Y. (1992) The regulation of subcortical dopamine systems by the prefrontal cortex: interactions of central dopamine systems and the pathogenesis of schizophrenia. J. neural Transm., Suppl. 36, 61-89.
22. Deutch A. Y., Bourdelais A. J. and Zahm D. S. (1993) The nucleus accumbens core and shell: accumbal compartments and their functional attributes. In Limbic Motor Circuit and Neuropsychiatry (eds Kalivas P. W. and Barnes C. D.), pp. 45-88. CRC Press, Boca Raton, FL.
23. Deutch A. Y., Clark W. A. and Roth R. H. (1990) Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res. 521, 311-315.
24. Deutch A. Y., Lee M. C., Gillham M. H., Cameron D., Goldstein M. and Iadorola M. J. (1991) Stress selectively increases Fos protein in dopamine neurons innervating the prefrontal cortex. Cerebral Cortex 1, 273-292.
25. Deutch A. Y., Lee M. C. and Iadorola M. J. (1992) Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: the nucleus accumbens shell as a locus of antipsychotic action. Molec. cell. Neurosci. 3, 332-341.
26. Deutch A. Y., Lewis D. A., Whitehead R. E., Cameron D. S., Redmond D. E. Jr and Roth R. H. (1993) Neuroleptics increase Fos expression in the striatal complex and temporal cortex of non-human primates. Soc. Neurosci. Abstr. 19, 134.
27. Deutch A. Y., Öngür D. and Duman R. S. (1995) Antipsychotic drugs induce Fos protein in the thalamic paraventricular nucleus: a novel locus of antipsychotic drug action. Neuroscience 66, 337-346.
28. Deutch A. Y., Moghaddam B., Innis R., Krystal J. H., Aghajanian G. K., Bunney B. S. and Charney D. S. (1991) Mechanisms of action of atypical antipsychotic drugs: implications for novel therapeutic strategies for schizophrenia. Schiz. Res. 4, 121-156.
29. Dragunow M. and Faull R. (1989) The use of c-fos as a metabolic marker in neuronal pathway tracing. J. Neurosci. Meth. 29, 261-265.
30. 2 dopamine receptor antagonists induce Fos and related proteins in striatal neurons. Neuroscience 37, 287-294.
31. Dragunow M., Leah J. D. and Faull R. L. M. (1991) Prolonged and selective induction of Fos-related antigen(s) in striatal neurons after 6-hydroxydopamine lesions of the rat substantia nigra pars compacta. Molec. Brain Res. 10, 355-358.
32. Duman R. S., Craig J. S., Winston S. M., Deutch A. Y. and Hernandez T. D. (1992) Amygdala kindling potentiates seizure-stimulated immediate early gene expression in rat cerebral cortex. J. Neurochem. 59, 1753-1760.
33. Ellenbroek B. (1993) Treatment of schizophrenia: a critical and preclinical evaluation of neuroleptic drugs. Pharmac. Ther. 57, 1-78.
34. Erdtsieck-Ernste E. B. H. W., Feenstra M. P. G., Botterblom M. H. A., van Uum H. F. M., Sluiter A. A. and Heinsbroek R. P. W. (1995) c-Fos expression in the rat brain after pharmacological stimulation of the rat "mediodorsal" thalamus by means of microdialysis. Neuroscience 66, 115-133.
35. Friedman L., Knutson L., Shurell M. and Meltzer H. Y. (1991) Prefrontal sulcal prominence is inversely related to response to clozapine in schizophrenia. Biol. Psychiat. 29, 865-877.
36. Friedman L., Jesberger J. A. and Meltzer H. Y. (1992) Effect of typical antipsychotic medications and clozapine on smooth pursuit performance in patients with schizophrenia. Psychiat. Res. 41, 25-36.
37. Grobin A. C. and Deutch A. Y. (1994) Apomorphine increases extracellular GABA levels in the prefrontal cortex of the freely moving, conscious rat. Soc. Neurosci. Abstr. 20, 1154.
38. Groenewegen H. J., Berendse H. W., Wolters J. G. and Lohman A. H. M. (1990) The anatomical relationship of the prefrontal cortex with the striatopallidal system, the thalamus, and the amygdala: evidence for a parallel organization. Prog. Brain Res. 85, 95-118.
39. Hendry S. H. C., Jones E. G., Emson P. C., Lawson D. E. M., Heizman C. W. and Streit P. (1989) Two classes of cortical GABA neurons defined by differential calcium binding protein immunoreactivities. Expl Brain Res. 76, 467-472.
40. 3 recognition sites: fact or artifact? Eur. J. Pharmac. 171, 137-139.
41. 2K) in the kidney inner medulla. Proc. natn. Acad. Sci. U.S.A. 88, 3170-3174.
42. Jenkins R., O'Shea R., Thomas K. L. and Hunt S. P. (1993) c-jun expression in substantia nigra neurons following striatal 6-hydroxydopamine lesions in the rat. Neuroscience 53, 447-455.
43. Julou L., Scatton B. and Glowinski J. (1977) Acute and chronic treatment with neuroleptics: similarities and differences in their actions on nigrostriatal, mesolimbic, and mesocortical dopaminergic neurons. Adv. Biochem. Psychopharmac. 16, 617-624.
44. Kane J. M., Honigfeld G., Singer J., Meltzer H. and the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. Arch. gen. Psychiat. 45, 789-796.
45. D28k-immunoreactive neurons in layer V of rat frontal cortex. J. Neurophysiol. 70, 387-396.
46. Kish S. J., Shannak K. and Hornykiewicz O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease: pathophysiological and clinical implications. New Engl. J. Med. 318, 876-880.
47. lc receptor antagonists. Eur. J. Pharmac. (Molec. Pharmac.) 245, 179-182.
48. Le Fur G., Guilloux F. and Uzan A. (1980) In vivo blockade of dopaminergic receptors from different rat brain regions by classical and atypical neuroleptics. Biochem. Pharmac. 29, 267-270.
49. Levin S. (1984) Frontal lobe dysfunctions in schizophrenia. II: impairments of psychological and brain functions. J. psychiat. Res. 18, 57-72.
50. Levy D. L., Holzman P. S., Matthysse S. and Mendell N. R. (1993) Eye tracking dysfunction and schizophrenia: a critical perspective. Schiz. Bull. 19, 461-536.
51. Lieberman J. A., Jody D., Alvir J. M. J., Ashtari M., Levy D. L., Bogerts B., Degreef G., Mayerhoff D. I. and Cooper T. (1993) Brain morphology, dopamine, and eye-tracking abnormalities in first-episode schizophrenia. Arch. gen. Psychiat. 50, 357-368.
52. Littman R. E., Hommer D. W., Clem T., Ornsteen M. L., Ollo C. and Pickar D. (1991) Correlation of Wisconsin Card Sorting Test performance with eye tracking in schizophrenia. Am. J. Psychiat. 148, 1580-1582.
53. 7) implicated in the regulation of mammalian circadian rhythms. Neuron 11, 449-458.
54. Lowry O. H., Rosebrough N. J., Farr A. L. and Randall R. J. (1951) Protein measurement with the Folin phenol reagent. J. biol. Chem. 193, 265-275.
55. Mansour A. and Watson S. J. (1995) Dopamine receptor expression in the CNS. In Psychopharmacology. The Fourth Generation of Progress (eds Bloom F. and Kupfer D.), pp. 207-220. Raven Press, New York.
56. i values. J. Pharmac. exp. Ther. 251, 238-246.
57. Miller J. C. (1990) Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs. J. Neurochem. 54, 1453-1455.
58. Moghaddam B. and Bunney B. S. (1990) Acute effect of typical and atypical anti-psychotic drugs on the release of dopamine from the prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54, 1755-1760.
59. 3 receptors. Eur. J. Pharmac. 238, 121-125.
60. Monsma F. J. Jr, Shen Y., Ward R. P., Hamblin M. W. and Sibley D. R. (1993) Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs. J. Pharmac. exp. Ther. 43, 320-327.
61. Nguyen T. V., Kasofsky B., Birnbaum R., Cohen B. M. and Hyman S. E. (1992) Differential expression of c-fos and Zif 268 in rat striatum following haloperidol, clozapine, and amphetamine. Proc. natn. Acad. Sci. U.S.A. 89, 4270-4274.
62. Nisoli E., Tonello C., Memo M. and Carruba M. O. (1992) Biochemical and functional identification of a novel dopamine receptor subtype in rat brown adipose tissue. Its role in modulating sympathetic stimulation-induced thermogenesis. J. Pharmac. exp. Ther. 263, 823-829.
63. Passingham R. E., Myers C., Rawlins N., Lightfoot V. and Fearn S. (1988) Premotor cortex in the rat. Behav. Neurosci. 102, 101-109.
64. Pisa M. and Schranz J. A. (1988) Dissociable motor roles of the rat's striatum conform to a somatotopic model. Behav. Neurosci. 102, 429-440.
65. Quinn J. P., Takimoto M., Iadarola M. J., Holbrook N. and Levens D. (1989) Distinct factors bind the AP-1 consensus sites in gibbon ape leukemia virum and simian virus 40 enhancers. J. Virol. 63, 1737-1742.
66. 3H]GABA on rat prefrontal cortical slices. Neuroscience 42, 61-71.
67. Robertson H. A., Peterson M. R., Murphy K. and Robertson G. S. (1989) D1-dopamine receptor agonists selectively activate c-fos independent of rotational behaviour. Brain Res. 503, 346-349.
68. Robertson G. S. and Fibiger H. C. (1992) Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine. Neuroscience 46, 315-328.
69. Rogers J. H. (1992) Immunohistochemical markers in rat cortex: co-localization of calretinin and calbindin-D28k with neuropeptides and GABA. Brain Res. 587, 147-157.
70. Rosin D. L., Clark W. A., Goldstein M., Roth R. H. and Deutch A. Y. (1992) Effects of 6-hydroxydopamine lesions of the prefrontal cortex on tyrosine hydroxylase activity in subcortical dopamine systems of the rat. Neuroscience 48, 831-839.
71. Rosse R. B., Schwartz B. L., Yim S. Y. and Deutsch S. I. (1993) Correlation between antisaccade and Wisconsin Card Sorting Test performance in schizophrenia. Am. J. Psychiat. 150, 333-335.
72. Sagar S. M., Sharp F. R. and Curran T. (1988) Expression of c-fos protein in brain: metabolic mapping at the cellular level. Science 240, 1328-1331.
73. Scherer-Singler U., Vincent S. R., Kimura H. and McGeer E. G. (1983) Demonstration of a unique population of neurons with NADPH-diaphorase histochemistry. J. Neurosci. Meth. 9, 229-234.
74. Sesack S. R. and Bunney B. S. (1989) Pharmacological characterization of the receptor mediating electrophysiological responses to dopamine in the rat medial prefrontal cortex: a microiontophoretic study. J. Pharmac. exp. Ther. 248, 1323-1333.
75. Sesack S. R., Deutch A. Y., Roth R. H. and Bunney B. S. (1989) The topographical organization of the efferent projections of the medial prefrontal cortex in the rat: an anterograde tract-tracing study using Phaseolus vulgaris leucoagglutinin. J. comp. Neurol. 290, 213-242.
76. Sesack S. R., Snyder C. L. and Lewis D. A. (1993) Synaptic associations between dopamine terminals and GABA interneurons in rat and monkey cortex. Soc. Neurosci. Abstr. 19, 382.5.
77. Smiley J. F. and Goldman-Rakic P. S. (1993) Heterogeneous targets of dopamine synapses in monkey prefrontal cortex demonstrated by serial section electron microscopy: a laminar analysis using the silver enhanced diaminobenzidine sulfide (SEDS) immunolabelling technique. Cerebral Cortex 3, 223-238.
78. 3) as a target for neuroleptics. Nature 347, 146-150.
79. Stevens J. R. (1973) An anatomy of schizophrenia? Arch. gen. Psychiat. 29, 177-189.
80. Swerdlow R. R. and Koob G. F. (1987) Dopamine, schizophrenia, mania, and depression: toward a unified hypothesis of cortico-striato-pallido-thalamic function. Behav. Brain Sci. 10, 197-245.
81. Thierry A. M., Blanc G., Sorbel A., Stinus L. and Glowinski J. (1973) Dopaminergic terminals in the rat cortex. Science 182, 499-501.
82. Thierry A. M., Le Douarin C., Penit J., Ferron A. and Glowinski J. (1986) Variation in the ability of neuroleptics to block the inhibitory influence of dopaminergic neurons on the activity of cells in the rat prefrontal cortex. Brain Res. Bull. 16, 155-160.
83. 4 receptor with high affinity for the antipsychotic clozapine. Nature 350, 610-614.
84. Verney C., Alvarez C., Geffard M. and Berger B. (1990) Ultrastructural double-labelling study of dopamine terminals and GABA-containing neurons in rat anteromedial cerebral cortex. Eur. J. Neurosci. 2, 960-972.
85. Wadenberg M.-L., Ahlenius S. and Svensson T. H. (1993) Potency mismatch for behavioral and biochemical effects by dopamine receptor antagonists: implications for the mechanisms of action of clozapine. Psychopharmacologia 110, 273-279.
86. Yamamoto B. K., Pehek E. A. and Meltzer H. Y. (1994) Brain region effects of clozapine on amino acid and monoamine transmission. J. clin. Psychiat. 55, Suppl. B, 8-14.